Communiqués Arrowhead Pharmaceuticals, Inc.

Actions

ARWR

US04280A1007

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/10/2026			Varia. 5j.	Varia. 1 janv.
60,74 ^USD	-1,20%		-6,25%	-8,51%

07/10	Arrowhead Pharmaceuticals, Inc. obtient l’admission de plozasiran au programme pilote STAR de la FDA pour l’hypertriglycéridémie sévère	CI
07/10	Arrowhead annonce que la FDA américaine a intégré le plozasiran à son programme pilote d’examen fractionné en temps réel des demandes	MT

Communiqués

07/10	Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia	BU
29/09	Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies	BU
15/09	Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
03/09	Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences	BU
30/08	Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia	BU
24/08	Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress	BU
18/08	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO(R) (plozasiran) as a New Treatment Option to Reduce Triglycerides	AQ
18/08	Arrowhead Pharmaceuticals - People Living with Familial Chylomicronaemia Syndrome in Germany Have Access to REDEMPLO as a New Treatment Option to Reduce Triglycerides	AQ
17/08	People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides	BU
04/08	Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results	BU
04/08	Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher	BU
03/08	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	BU
27/07	Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	BU
22/07	Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia	BU
21/07	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results	BU
23/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome	AQ
22/06	Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)	BU
18/06	Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars	BU
02/06	Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events	BU
27/05	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	BU
26/05	Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress	BU
14/05	Arrowhead Pharmaceuticals : ECO 2026 LBP4078 Kerr Activin E Poster 6May2026 FINAL	PU
13/05	Arrowhead Pharmaceuticals : TIDES 2026 KM final (1)	PU
08/05	Arrowhead Pharmaceuticals : ARWR FQ2 2026 Script FINAL	PU
07/05	Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results	BU